To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
PIONEER
A Molecular Epidemiology Study in Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) of Adeno Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
1 other identifier
interventional
1,270
7 countries
36
Brief Summary
The purpose of this study is to study the changes in protein in lung cells of Asian patients with advanced non small cell lung cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2010
Shorter than P25 for not_applicable
36 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 16, 2010
CompletedFirst Posted
Study publicly available on registry
August 19, 2010
CompletedStudy Start
First participant enrolled
September 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2011
CompletedAugust 8, 2011
August 1, 2011
10 months
August 16, 2010
August 5, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
EGFR mutation status of Asian patients with advanced NSCLC
Samples will be tested after informed consent. Mutation results will be available within 1-3 weeks.
Study Arms (1)
1
OTHEREGFR mutation testing
Interventions
Eligibility Criteria
You may qualify if:
- Histological or cytologically confirmed advanced Non small cell lung cancer of adeno histology NSCLC treatment naive Availability of cancer tissue or cytology sample
You may not qualify if:
- Involvement in the planning and/or conduct of the study Previous enrollment in the present study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (36)
Research Site
Beijing, Beijing Municipality, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shijiazhuang, Hebei, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changchun, Jilin, China
Research Site
Shenyang, Liaoning, China
Research Site
Jinan, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Hong Kong, Hong Kong, Hong Kong
Research Site
Chennai, Chennai, India
Research Site
Vadodara, Gujarat, India
Research Site
Kochi, Kerala, India
Research Site
Kolkata, Kolkata, India
Research Site
Mumbai, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Rohini, National Capital Territory of Delhi, India
Research Site
Cebu City, Philippines
Research Site
City of Taguig, Philippines
Research Site
Manila, Philippines
Research Site
Pasay, Philippines
Research Site
Quezon City, Philippines
Research Site
Chiayi City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Bangkok, Bangkok, Thailand
Research Site
Songkhla, Changwat Songkhla, Thailand
Research Site
Chiang Mai, Chiang Mai, Thailand
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Guy Yeoman, MBBS, MFPM
AstraZeneca
- STUDY CHAIR
Robin Meng, MD, PhD
AstraZeneca Taiwan
- PRINCIPAL INVESTIGATOR
Yang Pan-Chyr, MD, PhD
National Taiwan University College of Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 16, 2010
First Posted
August 19, 2010
Study Start
September 1, 2010
Primary Completion
July 1, 2011
Study Completion
July 1, 2011
Last Updated
August 8, 2011
Record last verified: 2011-08